Based on biomarker status, patients were categorized into four subtypes: 43 subjects (5.2%) were categorized as Luminal A subtype breast cancer, 489 subjects (59.1%) had a Luminal B breast cancer, 148 subjects (17.9%) had HER2-enriched breast cancer, and 148 cases (17.9%) had TN breast cancer. This evidence concerns the gene ERBB2 and breast cancer.